Literature DB >> 12399356

Discontinuation of thioridazine. Risks must be balanced.

Ann F Bisset.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12399356      PMCID: PMC1124456          DOI: 10.1136/bmj.325.7370.967/a

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  4 in total

1.  Timing of new black box warnings and withdrawals for prescription medications.

Authors:  Karen E Lasser; Paul D Allen; Steffie J Woolhandler; David U Himmelstein; Sidney M Wolfe; David H Bor
Journal:  JAMA       Date:  2002-05-01       Impact factor: 56.272

Review 2.  Discontinuation of thioridazine in patients with learning disabilities: balancing cardiovascular toxicity with adverse consequences of changing drugs.

Authors:  Simon J C Davies; Leila B Cooke; Alan G Moore; John Potokar
Journal:  BMJ       Date:  2002-06-22

3.  Chronic treatment with eltoprazine does not lead to tolerance in its anti-aggressive action, in contrast to haloperidol.

Authors:  J Mos; H H van Aken; R van Oorschot; B Olivier
Journal:  Eur Neuropsychopharmacol       Date:  1996-03       Impact factor: 4.600

4.  Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo-controlled cross-over study.

Authors:  R Vanden Borre; R Vermote; M Buttiëns; P Thiry; G Dierick; J Geutjens; G Sieben; S Heylen
Journal:  Acta Psychiatr Scand       Date:  1993-03       Impact factor: 6.392

  4 in total
  1 in total

Review 1.  ROS-Mediated Therapeutic Strategy in Chemo-/Radiotherapy of Head and Neck Cancer.

Authors:  Gan Huang; Shu-Ting Pan
Journal:  Oxid Med Cell Longev       Date:  2020-07-22       Impact factor: 6.543

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.